Victory Capital Management
OPNT

Victory Capital Management’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Victory Capital Management’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-674
Closed -$6K – 3510
2020
Q1 		$6K Buy
+674
New +$8.07K ﹤0.01% 3253
2019
Q4 		– Sell
-683
Closed -$10K – 3496
2019
Q3 		$10K Buy
+683
New +$9.52K ﹤0.01% 3279

Other funds holding OPNT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return

Victory Capital Management's OPNT Position: Q2 2020 in Review

Victory Capital Management sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2020, closing a stake of 674 shares — an estimated $6K sold.

Victory Capital Management first reported a position in OPNT in Q3 2019 and held it in 2 quarters. The position peaked at $10K in Q3 2019. 30 funds tracked by Wall St. Rank hold OPNT as of Q2 2020.

  • Victory Capital Management reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 674 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $10K in Q3 2019.
  • 30 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.